Poseidon Innovation

About Poseidon Innovation

Poseidon Innovation operates as a strategic collaboration formed in 2018 between the University of California San Diego (UC San Diego) and Deerfield Management, a healthcare-focused investment firm. The entity's primary function is to serve as a translational research accelerator, identifying and financing promising early-stage scientific projects originating from UC San Diego laboratories. Its core mission is to bridge the funding gap for high-risk, preclinical research, thereby speeding up the drug development cycle for novel, life-saving therapeutics.

The business model is centered on a substantial $65 million initial funding commitment from Deerfield Management. This capital is deployed to support selected research projects led by Principal Investigators at UC San Diego, covering the preclinical activities required to file an Investigational New Drug (IND) application. Poseidon Innovation is governed by a joint steering committee with members from both UC San Diego and Deerfield, which is responsible for project selection and oversight. Revenue generation for the collaborators is envisioned through the commercial potential of the developed therapies, with Deerfield Management positioned to make additional capital investments into spin-off companies that emerge from successful projects.

The company serves a specific client base: full-time Principal Investigators and faculty at UC San Diego who are engaged in therapeutic research across all disease areas. Through a formal request-for-proposal (RFP) process held twice a year, researchers can apply for funding. This structure provides a direct pathway for academic discoveries to progress toward clinical application, backed by Deerfield's financial resources and expertise in drug development. The collaboration leverages UC San Diego's extensive research capabilities and Deerfield's industry experience to de-risk and advance potential cures for a wide range of diseases.